Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral ...

The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Novo Nordisk's Karsten Munk Knudsen is targeting 800 million obese people globally.

The weight loss injection Mounjaro is a new treatment that can now be delivered to customers' homes by a new clinic service offered by Morrisons.

Novo Nordisk reported turnover from obesity treatments soared by 57 per cent to 65.1 billion Danish kroner last year, largely ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...

A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.